CFD’er er komplekse instrumenter, og der er en stor risiko forbundet med disse for at miste penge på grund af gearing. 85.4 % af detailinvestorerne har tab på deres konto, når de handler CFD’er med denne udbyder. Du skal overveje, om du forstår, hvordan CFD’er fungerer, og om du har råd til at løbe en stor risiko for at miste dine penge.

Close

Handel Bristol Myers BMY

Sælge
 Køb

BristolMyers live diagram

5m 15m 30m 1h 4h 1d 1w

Grundlæggende Instrumenter

Weekly Search
Weekly
Daily
Dato Luk Ændring % Ændre Åbn Høj Lav

BristolMyers news

Seneste nyheder

Info

Spread

0.35

Spread (%)

0.6066 %

Gearing

1:5

Dag til dag-rente Køb

-0.0597 %

Dag til dag-rente Sælg

-0.0292 %

Valuta

USD

Åbningstider for handel

Market lukket

Fredag

13:31 - 19:59

Mandag

13:31-19:59

Tirsdag

13:31-19:59

Onsdag

13:31-19:59

Torsdag

13:31-19:59

Analyse og statistikker

Åbn

---

Forrige luk

---

52 uger høj/lav

--- – ---

Markedsværdi

118317604864

Aktier udestående

2042071247

Indtjeningsdato (Næste)

2001-08-07

Udbytteprocent

2026-08-03

Ex-udbyttedato

2026-07-02

Forventet årlig udbyttesats

2.52

Forventet årlig udbytteprocent

0.0438

EPS

3.57

Få mere at vide om dette instrument

Bristol Myers Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Relaterede instrumenter

Aktiv
Sælge
Køb
% Ændre

Handl nu

Handl nu

Handl nu

Handl nu

latest_education_articles

Trustpilot